Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp.verified

MDNA

Price:

$0.157

Market Cap:

$14.94M

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a ...[Read more]

Industry

Biotechnology

IPO Date

2017-11-13

Stock Exchange

NASDAQ

Ticker

MDNA

The PE Ratio as of April 2024 (TTM) for Medicenna Therapeutics Corp. (MDNA) is -1.74

According to Medicenna Therapeutics Corp.’s latest financial reports and current stock price. The company's current PE Ratio is -1.74. This represents a change of -53.28% compared to the average of -3.72 of the last 4 quarters.

Medicenna Therapeutics Corp. (MDNA) Historical PE Ratio (quarterly & annually)

How has MDNA PE Ratio performed in the past?

The mean historical PE Ratio of Medicenna Therapeutics Corp. over the last ten years is -58.93. The current -1.74 PE Ratio has changed 195.28% with respect to the historical average. Over the past ten years (40 quarters), MDNA's PE Ratio was at its highest in in the December 2016 quarter at -1.61. The PE Ratio was at its lowest in in the June 2015 quarter at -205.55.

Quarterly (TTM)
Annual

Average

-58.93

Median

-14.34

Minimum

-212.58

Maximum

35.65

Medicenna Therapeutics Corp. (MDNA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Medicenna Therapeutics Corp. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 241.16%

Maximum Annual PE Ratio = 35.65

Minimum Annual Increase = -1028.77%

Minimum Annual PE Ratio = -212.58

Quarterly (TTM)
Annual
YearPE RatioChange
202335.65-1028.77%
2022-3.84-74.05%
2021-14.796.51%
2020-13.89241.16%
2019-4.07-38.87%
2018-6.66-74.96%
2017-26.59-81.06%
2016-140.40-33.96%
2015-212.585.18%

Medicenna Therapeutics Corp. (MDNA) Average PE Ratio

How has MDNA PE Ratio performed in the past?

The current PE Ratio of Medicenna Therapeutics Corp. (MDNA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

5.67

5-year avg

-0.19

10-year avg

-58.93

Medicenna Therapeutics Corp. (MDNA) PE Ratio vs. Peers

How is MDNA’s PE Ratio compared to its peers?

Medicenna Therapeutics Corp.’s PE Ratio is less than Achilles Therapeutics plc (-0.47), less than Checkpoint Therapeutics, Inc. (-0.93), less than Cue Biopharma, Inc. (-1.47), greater than Pieris Pharmaceuticals, Inc. (-48.48), greater than Eliem Therapeutics, Inc. (-3.31), less than Ikena Oncology, Inc. (-0.94), less than Ovid Therapeutics Inc. (0.15), less than Connect Biopharma Holdings Limited (-0.00), greater than Edgewise Therapeutics, Inc. (-10.31), less than Protara Therapeutics, Inc. (-0.89), less than Vaccinex, Inc. (-0.23), less than Monopar Therapeutics Inc. (-1.13), greater than Miromatrix Medical Inc. (-3.41), less than Surrozen, Inc. (-0.43), less than Passage Bio, Inc. (-0.63), less than Magenta Therapeutics, Inc. (-0.04), greater than TRACON Pharmaceuticals, Inc. (-12.46), less than Invivyd, Inc. (-1.28), less than Aptevo Therapeutics Inc. (-0.04), greater than Werewolf Therapeutics, Inc. (-6.21), less than Oncorus, Inc. (-0.04), less than SAB Biotherapeutics, Inc. (-0.62), less than Akari Therapeutics, Plc (-0.74),

Build a custom stock screener for Medicenna Therapeutics Corp. (MDNA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Medicenna Therapeutics Corp. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Medicenna Therapeutics Corp. (MDNA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Medicenna Therapeutics Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Medicenna Therapeutics Corp.'s PE Ratio?

How is the PE Ratio calculated for Medicenna Therapeutics Corp. (MDNA)?

What is the highest PE Ratio for Medicenna Therapeutics Corp. (MDNA)?

What is the 3-year average PE Ratio for Medicenna Therapeutics Corp. (MDNA)?

What is the 5-year average PE Ratio for Medicenna Therapeutics Corp. (MDNA)?

How does the current PE Ratio for Medicenna Therapeutics Corp. (MDNA) compare to its historical average?